MedTrace Logo

The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

NCT04659239 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34020

Last updated 2021-02-10

No results posted yet for this study

Summary

This is a randomized, double-blinded, placebo controlled phase III clinical trial to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after 2-dose schedule.

Conditions

Interventions

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell)

The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.

BIOLOGICAL

Placebo

The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Yasmin binti Mohamed Gani, PhD · Hospital Sungai Buloh

  • Adilson JW Cavalcante, PhD · CEMEC Pesquisa Clinica

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2021-09-30
Completion
2022-07-31

Countries

  • Brazil
  • Malaysia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04659239 on ClinicalTrials.gov